A Phase 2, Open-label, Randomized, Two-part, Multiple Dose Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic Hepatitis B Virus

Trial Profile

A Phase 2, Open-label, Randomized, Two-part, Multiple Dose Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic Hepatitis B Virus

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2018

At a glance

  • Drugs Inarigivir soproxil (Primary) ; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ACHIEVE
  • Sponsors Spring Bank Pharmaceuticals
  • Most Recent Events

    • 16 Apr 2018 Treatment arms has been changed from 13 to 10 arms and patient number also decreased.
    • 16 Apr 2018 Planned number of patients changed from 300 to 200.
    • 16 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Jul 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top